Simulations Plus (NASDAQ:SLP) Releases FY 2025 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 1.070-1.200 for the period, compared to the consensus estimate of 1.090. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $90.4 million. Simulations Plus also updated its FY25 guidance to $1.07-1.20 EPS.

Simulations Plus Trading Up 7.8 %

Shares of SLP opened at $25.68 on Friday. Simulations Plus has a 12-month low of $23.01 and a 12-month high of $51.22. The stock has a market cap of $515.96 million, a P/E ratio of 64.20 and a beta of 0.89. The company has a 50-day moving average of $30.03 and a two-hundred day moving average of $30.29.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings data on Thursday, April 3rd. The technology company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.06. The firm had revenue of $22.43 million during the quarter, compared to the consensus estimate of $21.93 million. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The company’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.20 EPS. As a group, analysts forecast that Simulations Plus will post 1.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on SLP. StockNews.com upgraded shares of Simulations Plus from a “sell” rating to a “hold” rating in a report on Friday. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, January 8th. Finally, KeyCorp lifted their price objective on Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.40.

Insider Activity

In related news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the transaction, the director now owns 3,402,584 shares in the company, valued at approximately $115,381,623.44. This trade represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 19.40% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.